This proposal aims to develop new bioactive materials to improve clinical outcomes for patients suffering from bone sarcoma. The developed materials will provide a control release of key metal ions to induce tumour cell death and simultaneously stimulate grow new bone. In addition the material will contain natural antibacterial agents to reduce the probability of surgical site infections. Furthermore we envisage that the material will enhance blood flow therefore significantly reducing patient healing times.
The material will be composed of calcium and phosphorous (the key building blocks of bone) and contain gallium, a metal widely used in cancer treatment and known to selectively target tumour cells. In addition the material will contain strontium which is antimicrobial and cobalt which is known to enhance blood vessel formation (blood flow can be a key factor for healing times). These metals will be hosted in a soluble bioactive material which will provide a controlled release of these ions, over an extended time period, directly at the surgical site.
Initial experiments will be conducted on cell lines in the laboratory to optimise these materials and their properties. It is anticipated these results will lead to additional experiments in animal models in the near future. The anticipated outcome is that novel materials will be developed that will significantly improve patient well-being, reduce the probability of tumours redeveloping or spreading to other sites, reduce the probability of surgical site infections whilst simultaneously helping new bone growth and reducing healing times accordingly.